Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
The CTMX news page on Stock Titan aggregates recent coverage and official announcements related to CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company listed on the Nasdaq Global Select Market. CytomX reports that it is developing novel, conditionally activated, masked biologics based on its PROBODY® therapeutic platform, with a focus on cancer indications such as advanced colorectal cancer and advanced melanoma.
Visitors to this page can review news items that describe the progress of CytomX’s clinical programs, including updates on varsetatug masetecan (Varseta-M, formerly CX-2051), a masked EpCAM-directed antibody-drug conjugate with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY® cytokine. Company press releases have discussed Phase 1 dose escalation and expansion activities, translational biomarker data, and plans for potential later-stage development in colorectal cancer and melanoma.
In addition to pipeline updates, CytomX news often includes financial results, business updates, and information about investor conference presentations. These items provide context on the company’s operating priorities, cash position, and interactions with the investment community. News releases also highlight research and collaboration activities involving its PROBODY® platform, such as work on T-cell engagers and cytokine-based approaches in partnership with other biopharmaceutical companies.
By following CTMX news, investors and researchers can monitor how CytomX describes the evolution of its PROBODY® technology, its clinical data disclosures, and its collaborations with partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. This page offers a centralized view of publicly released information that may be relevant to understanding the company’s development-stage oncology pipeline and corporate activities.
CytomX Therapeutics (Nasdaq: CTMX) will present initial Phase 1 translational biomarker data for CX-801 (PROBODY interferon alpha-2b) at SITC 2025 (Nov 7–9).
Data demonstrate tumor-selective activation of interferon signaling and induction of immune cell populations and interferon-stimulated genes (including PD-1 and PD-L1) in paired tumor biopsies, and are reported as generally well tolerated in patients with metastatic melanoma refractory to prior checkpoint inhibitors. CytomX says these findings support the ongoing Phase 1 combination study of CX-801 with KEYTRUDA, with combination clinical data expected in 2026.
Poster: “Pharmacodynamic Activity of CX-801…” (Abstract 606) on Nov 8, 2025, 5:10–6:35 PM ET. Additional preclinical poster for CX-908 (Abstract 961) on Nov 7, 2025.
CytomX Therapeutics (Nasdaq: CTMX) will report its third quarter 2025 financial results on Thursday, November 6, 2025, after the close of U.S. markets.
The company will host a conference call and live webcast on November 6, 2025 at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the live webcast via the company’s Events and Presentations page and are advised to register at least 10 minutes before the call. An archived replay of the webcast will be available on the company website.
CytomX Therapeutics (Nasdaq: CTMX) on October 20, 2025 appointed Rachael Lester as Senior Vice President, Chief Business Officer to lead strategy and business development.
The company highlighted Lester’s two decades of experience in corporate strategy, partnerships and capital formation, citing prior roles as chief business officer at Replicate Bioscience, SVP of business development at Harpoon Therapeutics (acquired by Merck), and senior roles at Bruin Biometrics and Onyx Pharmaceuticals. Management said Lester will drive partnering and expand the PROBODY® platform while supporting lead clinical assets CX-2051 and CX-801 aimed at colorectal cancer and melanoma.
CytomX Therapeutics (NASDAQ: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in three major investor conferences this September in New York.
The company will present at the Cantor Global Healthcare Conference (September 4), the H.C. Wainwright Global Investment Conference (September 9), and the Morgan Stanley Global Healthcare Conference (September 10). All presentations will be available via webcast on the company's website, and management will be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (NASDAQ:CTMX) provided an update on its Phase 1 study of CX-2051 for colorectal cancer treatment. The CTMX-2051-101 study has successfully enrolled 73 patients across three dose expansion cohorts (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W), with approximately 20 patients per dose level.
The company reported a single Grade 5 treatment-related adverse event involving acute kidney injury in a patient with a complex medical history. Following this event, reported to the FDA on July 18, 2025, the Safety Review Committee supported continued study execution. CytomX remains on track to provide a Phase 1 data update in Q1 2026.
CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2025 financial results and significant clinical progress. The company announced positive interim data from Phase 1 study of CX-2051, their first-in-class EpCAM Antibody Drug Conjugate for advanced colorectal cancer, with Phase 2 study initiation planned for 1H 2026. CytomX also initiated combination dose escalation of CX-801 with KEYTRUDA® for advanced melanoma.
Financially, CytomX completed a $100 million common stock offering and ended Q2 2025 with $158.1 million in cash. Revenue was $18.7 million, down from $25.1 million year-over-year. Operating expenses decreased to $19.9 million from $33.6 million in Q2 2024. The company expects its cash runway to extend to Q2 2027.
CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, will release its second quarter 2025 financial results on Thursday, August 7, 2025, after U.S. markets close.
The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Investors can access the live webcast through CytomX's investor relations website and are advised to register at least 10 minutes before the call. A replay will be available on the company's website after the event.
CytomX Therapeutics (NASDAQ: CTMX), a company specializing in masked, conditionally activated biologics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO and Chairman Sean McCarthy will engage in a fireside chat on June 5, 2025, at 2:35 p.m. ET. The presentation will be accessible via live webcast on the company's website at www.cytomx.com under the Events and Presentations section. The company's management team will also be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (NASDAQ:CTMX) has announced the pricing of an underwritten public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million in gross proceeds. The offering, expected to close on May 13, 2025, features participation from notable investors including Longitude Capital, OrbiMed, Venrock Healthcare Capital Partners, Vivo Capital, and RTW Investments.
The company plans to use the proceeds for research and development, general corporate purposes, and working capital needs. Jefferies and Piper Sandler are serving as joint book-running managers for the offering, which is being conducted through an effective shelf registration statement filed with the SEC.